Currently, advances relating to cancer care like immunotherapy are promising considerable success in treatment even though they pose greater risks and unforeseen results.
Vanderbilt University Medical Center and GE Healthcare are collaborating to create artificial intelligence (AI) apps with the ability to examine anonymized data belonging to the patient in a bid to assist physicians in determining better treatments.
Through retroactively assessing imaging, proteomic, cellular, genomic, tumor, and demographic data drawn from anonymized patient data, the AI applications are expected to help clinicians in deciding the ideal form of treatment for both future and current patients.
“This partnership is a great example of the increasing convergence of the tools, technologies and data used by therapy innovators and healthcare providers,” said Kieran Murphy, the president and chief executive officer of GE Healthcare, in a statement.
Since immunotherapies are costly and boast the ability to trigger damage in case the inappropriate therapy is picked, they are still linked with increased costs and mortalities.
Making well-informed choices regarding the possible effectiveness of a particular treatment will allow physicians to cut costs and provide more outcomes, specifically for patients.
Artificial intelligence (AI)-powered clinical decision and analysis support like this are expected to spearhead an increased adoption of a given course of precision cancer treatment through accurately forecasting how a patient would respond to a particular therapy.
Artificial intelligence (AI) is currently being used in making sense out of under-analyzed health records.
The insights it is capable of gathering by going through a huge set of patient records can assist in not only informing personalized healthcare but also in leading health systems in better understanding how various treatment options operate.
Even though the potential of precision health records is considerable, such data is still held in silos.
With more collaborations forming around the provision of AI-driven clinical support and retroactive analysis of medical data, physicians are anticipated to make improved decisions that are supported by an array of newly-accessed records.
“Immunotherapy offers tremendous promise but given the current unpredictability of some patients’ reactions to treatments, it is also associated with increased morbidity and cost.
This partnership provides the opportunity to leverage strengths of both of our organizations to further personalize cancer care by creating new tools that allow clinicians to more accurately predict how patients will respond to a specific therapy,” said Dr. Jeff Balser, president and chief executive officer of Vanderbilt University Medical Center.
